VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SPRY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SPRYARS Pharmaceuticals, Inc.
$3.69$366M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksSPRYQuarterly Financials

ARS Pharmaceuticals, Inc. (SPRY) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

ARS Pharmaceuticals, Inc. (SPRY) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

SPRY Income Statement

Quarterly statement

SPRY Income Statement

ARS Pharmaceuticals, Inc. (SPRY) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21
Sales/Revenue37.71M33.66M22.68M28.09M32.5M15.72M7.97M86.58M2.07M500K00010K20K0189K464K663K754K
Revenue Growth %16.03%114.15%184.47%-67.56%1471.62%3043.4%---4900%-100%--100%-97.84%-96.98%-100%-64.2%-78.03%-68.61%-
Cost of Goods Sold012.85M6.29M3.2M8.19M4.98M4.05M3.89M112K6.9M5.23M3.4M3M7.21M6.45M3.55M3.79M4.35M5.42M3.91M
COGS % of Revenue-38.17%27.71%11.4%25.2%31.71%50.75%4.5%5.42%1379.2%---72080%32260%-2006.88%937.5%817.95%519.1%
Gross Profit020.81M16.39M24.89M24.31M10.73M3.93M82.69M1.96M-6.4M-5.23M-3.4M-3M-7.2M-6.43M-3.55M-3.6M-3.89M-4.76M-3.16M
Gross Margin %-61.83%72.29%88.6%74.8%68.29%49.25%95.5%94.58%-1279.2%----71980%-32160%--1906.88%-837.5%-717.95%-419.1%
Gross Profit Growth %-100%93.91%317.49%-69.91%1142.84%267.81%175.03%2529.17%165.16%11.14%18.63%4.22%16.7%-85.23%-35.13%-12.47%21.55%-10.82%-35.75%-
Operating Expenses71.88M82.28M76.54M66.35M77.5M58.35M41.1M35.49M23.7M8.94M7.96M6.82M14.98M13.4M12.28M11.89M3.03M2.46M2.34M1.8M
OpEx % of Revenue190.62%244.45%337.46%236.23%238.46%371.23%515.54%40.99%1146.23%1788.8%---134050%61405%-1601.06%529.74%352.79%238.86%
Selling, General & Admin43.52M77.58M72.2M59.95M74.75M54.31M0019.28M8.94M00013.4M12.28M10.83M3.03M2.46M2.34M1.8M
SG&A % of Revenue115.41%230.49%318.35%213.46%230%345.56%--932.35%1788.8%---134050%61405%-1601.06%529.74%352.79%238.86%
Research & Development18.26M4.7M4.34M3.44M2.75M4.04M2.95M3.03M4.42M6.9M5.23M3.4M3M7.31M6.55M4.71M3.89M4.35M5.42M3.91M
R&D % of Revenue48.43%13.96%19.12%12.26%8.46%25.67%37.03%3.5%213.88%1379.2%---73080%32760%-2059.79%937.5%817.95%519.1%
Other Operating Expenses1000K001000K001000K1000K0-1000K1000K1000K1000K-1000K-1000K-1000K-1000K-1000K-1000K-1000K
Operating Income-34.17M-61.47M-60.15M-41.47M-53.19M-47.61M-37.18M47.2M-21.75M-15.34M-13.19M-10.23M-17.98M-20.6M-18.71M-15.44M-6.63M-6.34M-7.1M-4.96M
Operating Margin %-90.62%-182.62%-265.18%-147.63%-163.66%-302.95%-466.29%54.51%-1051.64%-3068%----206030%-93565%--3507.94%-1367.24%-1070.74%-657.96%
Operating Income Growth %35.76%-29.09%-61.78%-187.86%-144.58%-210.39%-181.81%561.54%-20.97%25.54%29.5%33.78%-171.16%-224.76%-163.6%-211.29%-18.06%-42.93%-59.94%-
EBITDA-34.17M-61.05M-59.75M-41.05M-50.84M-47.34M-36.9M47.35M-21.73M-15.32M-13.18M-10.21M-17.96M-20.58M-18.69M-15.19M-6.62M-6.34M-7.05M-4.75M
EBITDA Margin %-90.62%-181.38%-263.43%-146.15%-156.43%-301.17%-462.77%54.69%-1050.63%-3064.4%----205830%-93465%--3504.23%-1365.84%-1063.2%-630.37%
EBITDA Growth %32.79%-28.97%-61.93%-186.68%-133.99%-208.93%-179.93%563.63%-20.99%25.56%29.49%32.75%-171.13%-224.78%-165.19%-219.53%-17.97%-42.83%-58.87%-
D&A (Non-Cash Add-back)0416K397K417K2.35M279K280K158K21K18K11K12K21K20K20K255.5K7K6.5K50K208K
EBIT0-59.86M-58.18M-41.4M-51.15M-44.88M-33.94M50.22M-19.13M-12.52M-10.29M-10.23M-17.98M-20.6M-18.71M-15.44M-6.63M-6.34M-7.1M-4.96M
Net Interest Income0-874K-473K000000000000000047K
Interest Income1.14M1.6M1.97M0000000000000-0-47K
Interest Expense-2.55M2.48M2.44M0000000000000-0--
Other Income/Expense-1.42M-874K-473K61K2.04M2.73M3.24M3.02M2.62M2.82M2.9M3.06M3.11M3.23M3.75M1.01M47K-76K-151K-179K
Pretax Income-35.59M-62.34M-60.62M-41.4M-51.15M-44.88M-33.94M50.22M-19.13M-12.52M-10.29M-7.17M-14.87M-17.37M-14.96M-14.43M-6.58M-6.42M-7.25M-5.14M
Pretax Margin %-94.37%-185.21%-267.26%-147.41%-157.38%-285.57%-425.69%58.01%-924.95%-2503.2%----173700%-74805%--3483.07%-1383.62%-1093.51%-681.7%
Income Tax000-80K000288K000000000000
Effective Tax Rate %0%0%0%0.19%0%0%0%0.57%0%0%0%0%0%0%0%0%0%0%0%0%
Net Income-35.59M-62.34M-60.62M-41.32M-51.15M-44.88M-33.94M49.93M-19.13M-12.52M-10.29M-7.17M-14.87M-17.37M-14.96M-14.43M-6.58M-6.42M-7.25M-5.14M
Net Margin %-94.37%-185.21%-267.26%-147.13%-157.38%-285.57%-425.69%57.67%-924.95%-2503.2%----173700%-74805%--3483.07%-1383.62%-1093.51%-681.7%
Net Income Growth %30.43%-38.89%-78.6%-182.76%-167.41%-258.61%-229.77%796.62%-28.67%27.94%31.21%50.32%-125.82%-170.56%-106.36%-180.72%-13.3%-38.17%-56.03%-
Net Income (Continuing)-35.59M-62.34M-60.62M-41.32M-51.15M-44.88M-33.94M49.93M-19.13M-12.52M-10.29M-7.17M-14.87M-17.37M-14.96M-14.43M-6.58M-6.42M-7.25M-5.14M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-0.36-0.63-0.61-0.42-0.52-0.46-0.350.51-0.20-0.13-0.11-0.07-0.16-0.18-0.16-0.15-0.07-0.07-0.08-0.15
EPS Growth %30.77%-36.96%-74.29%-182.35%-160%-253.85%-218.18%783.65%-25%27.78%31.25%50.27%-127.92%-162.77%-106.99%0%58.71%47.31%40.54%-
EPS (Basic)-0.36-0.63-0.61-0.42-0.52-0.46-0.350.51-0.20-0.13-0.11-0.07-0.16-0.18-0.16-0.15-0.07-0.07-0.08-0.15
Diluted Shares Outstanding99.69M99.31M99.3M98.57M98.81M98.36M98.06M97.95M97.03M96.83M96.49M96.13M95.58M94.91M94.23M94M93.77M93.77M93.77M35.04M
Basic Shares Outstanding99.69M99.31M99.3M98.57M98.81M98.36M98.06M97.95M97.03M96.83M96.49M96.13M95.58M94.91M94.23M94M93.77M93.77M93.77M35.04M
Dividend Payout Ratio--------------------